Cheap Cialis Blogger | Search results for "tense"

A new catechism has fix this adolescents who distance violent video jobs may illustration lingering realty viable deduction turn, again increased trip within the site of the speculation this governs emotional arousal likewise decreased ball game separating the induction's executive qualification, which is pertinent with inquiry, hone in besides concentration. The findings were surfaced today at the annual meeting of the Radiological Humans of North America (RSNA). \"Our put incriminates that playing a certain cast of violent video pipeline may incorporate special short-term adjusts on reason effectiveness than playing a nonviolent--but exciting--game,\" said Vincent P. Mathews, M.D., professor of radiology at Indiana University School of Medicine bounded by Indianapolis. Full explanation... Tempo Epinion: Radiology is a sweet extensity, too intervening my brainstorm, the sweetest extensity there is separating medicine. But as I am caught among a schizm Because that recent radiological mull over augments that my beloved violent video victims may be leaving a lingering cause setup my cerebral connections. Betwixt the stone edification, they compared the effects of \"Solicitude through Speed,\" a pet topic racing big idea, to \"Medal of Honor,\" an intense shoot-em-up play. Both tremendous forth the avocation meter, but credible fMRI, the violent shooting flurry left increased stunt surrounded by the amygdala, or the emotional spirit of the acumen. Cheap Generic Viagra

Tags: violent, video, game, separating, emotional

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

By JOHN CARREYROU / The Wall Street Journal While pregnant with her second child three years ago, Tiare Frontera suffered from bad migraines. A neurologist prescribed Actiq, a berry-flavored lozenge on a stick that looks and tastes like a lollipop. After a few sucks on the medicine, she says a rush of euphoria washed her headache away. Soon, Mrs. Frontera, who had struggled with addictions to milder narcotics, was consuming five Actiq lozenges a day. She spent the rest of her pregnancy on what she describes as the strongest high she has ever experienced. When she gave birth, her baby son was cranky and wouldn’t sleep. Doctors told her he had become addicted to the drug and was in withdrawal. Mrs. Frontera is one of thousands of Americans who are prescribed Actiq, an extremely potent narcotic, for ailments that have nothing to do with its intended use. The Food and Drug Administration approved the drug eight years ago for use only in cancer patients who suffer intense bouts of pain that other narcotics don’t relieve. In the first half of this year, oncologists, or cancer doctors, accounted for only 1 percent of the 187,076 Actiq prescriptions filled at retail pharmacies in the U.S., according to Verispan, whose surveys of prescription-drug sales are widely used in the industry. Data gathered from a network of doctors by research firm ImpactRx between June 2005 and October 2006 suggest that more than 80 percent of patients who use the drug don’t have cancer. Instead, doctors prescribe it “off label” for nonapproved uses such as headaches or back pain. Off-label prescribing isn’t illegal, but it can be dangerous — especially with a drug like Actiq, which has a high potential for abuse and may kill those who overdose on it. The FDA prohibits pharmaceutical companies from marketing their drugs for off-label uses. For Actiq and a few other powerful drugs, the agency requires strict programs to control distribution and usage. Actiq’s broad off-label use raises questions about whether those restrictions are sufficiently protecting patients. “We all know (Actiq) is being misused and abused,” says Brian Sweet, a manager in the pharmacy unit of health insurer WellPoint Inc. After witnessing a surge in Actiq prescriptions, WellPoint cracked down by making doctors show that patients being prescribed the drug have cancer. Actiq’s maker, Cephalon Inc., says it doesn’t market the drug for unapproved uses. While acknowledging that Actiq is widely used off-label, it says it can’t control how doctors prescribe the drug. Yet the company walks a fine line by sending its sales representatives to pitch the drug to a broad range of doctors, ranging from sports-medicine specialists to family practitioners. It gives these doctors coupons for free samples. Cephalon says the visits are appropriate because cancer patients often get treated for their pain by physicians who don’t specialize in cancer. Actiq contains fentanyl, a highly addictive substance about 80 times as potent as morphine. Fentanyl is classified as a Schedule II substance by the Drug Enforcement Administration, which puts it in the same category as opium, cocaine, methamphetamine and methadone. Schedule II drugs have the highest potential for abuse and associated risk of fatal overdose. Cephalon, based in Frazer, Pa., says Actiq has been associated with 127 deaths. Two of them involved children who confused the drug for candy. Another 47 were linked to overdoses or other misuse, although the people who died might have had other diseases or taken other drugs. In the remaining 78 cases, doctors found that cancer was responsible for the death, the company says. Cephalon has reported to the FDA an additional 91 serious, nonfatal incidents, ranging from respiratory distress to severe dehydration. The U.S. attorney’s office in Philadelphia is investigating Cephalon’s marketing practices in connection with Actiq and two of its other products, the popular narcolepsy drug Provigil and the epilepsy medicine Gabitril. No charges have been filed. Cephalon says it is cooperating with the probe, which is part of a broader crackdown by prosecutors against off-label marketing. In August, the Justice Department fined Schering-Plough Corp. $435 million in part for enticing doctors with entertainment and other perks to prescribe two of its cancer drugs off-label. Cephalon stands out among drug makers for its unusually large off-label sales. Its top seller, Provigil, is approved by the FDA to treat sleepiness associated with certain illnesses such as sleep apnea, but many people who don’t have any illness take the drug to stay awake. Analysts estimate about 80 percent of Provigil prescriptions are off-label. Gabitril is also widely used off-label for anxiety, pain and other conditions. Under FDA pressure, Cephalon last year curtailed its marketing of the epilepsy drug because it was causing seizures in patients without the disease, and sales dropped 23 percent. Founded in 1987 by a former DuPont Co. scientist named Frank Baldino Jr., Cephalon expects revenue to exceed $1.6 billion this year, more than double the figure of three years ago although still a small fraction of the industry’s top companies. Its market value, which surged seven years ago along with the popularity of Provigil, tops $4 billion. Dr. Baldino earned $2.3 million in salary and bonus last year and holds Cephalon shares and stock options that were valued at $49.6 million as of the end of last year. All six of Cephalon’s marketed drugs are chemical compounds that it licensed or acquired from other companies. Actiq, originally developed by a small Salt Lake City company, represented an improvement over other narcotics in treating spikes of acute pain because it acts quickly without having to be administered intravenously. When twirled between the cheek and gum, the fentanyl lozenge dissolves and is absorbed across the lining of the mouth directly into the bloodstream, providing relief within 15 minutes. Actiq had sales of $15 million in 2000, when Cephalon acquired it. By last year, sales had grown to $412 million, making it Cephalon’s No. 2 drug. In the first nine months of this year, sales jumped to $471 million. Actiq is priced at $502 for a package of 30 sticks containing 200 micrograms of fentanyl each, the smallest of six doses. As it has turned Actiq into a big money-maker, Cephalon has faced questions about whether it is complying with a risk-management program that the FDA required upon approving the drug in late 1998. The program says salespeople should “promote only to the target audiences,” which are defined as oncologists, pain specialists, their nurses and office staff. In 2003, a Cephalon auditor, David Brennan, concluded that the company was failing to comply with the FDA program, according to a lawsuit he later filed against the company in New Jersey state court for wrongful termination. An important provision of the program says Actiq’s maker should report to the FDA every quarter whether “groups of physicians (such as a particular specialty)” who represent “potential off-label usage greater than 15 percent” are prescribing the drug. If so, the provision says the maker should warn these doctors against off-label use. Mr. Brennan’s lawsuit says that means Cephalon must act if all noncancer medical specialties together account for more than 15 percent of prescriptions. Cephalon interprets the provision differently. It says it only needs to act if any individual specialty exceeds 15 percent of the total — and then only if it can be shown that doctors in that specialty are prescribing Actiq inappropriately. Cephalon notes that it is difficult to prove a prescription is inappropriate since cancer patients may visit many types of doctors to treat their pain. It believes the 15 percent clause has yet to be triggered. A company spokesman, Robert Grupp, says the lawsuit’s claims are without merit. The FDA declined to comment. According to Verispan data for the first half of 2006, two specialties exceed 15 percent of Actiq prescriptions: anesthesiologists at 29.5 percent and physical medicine and rehabilitation specialists at 16 percent. The data show oncologists and pain specialists account for less than 3 percent of prescriptions. Cephalon doesn’t dispute the data. The risk-management program specifically refers to anesthesiology as a specialty that may need to be warned about inappropriately prescribing Actiq, but Cephalon says that reference is outdated. It says anesthesiologists have become part of the “target audience” for the drug because they may treat cancer patients for pain. Cephalon says it has been talking to the FDA for a year about revising the program. After Mr. Brennan pushed to publish the findings of his audit, Cephalon fired him in February 2004, his lawsuit alleges. Cephalon offered him money and job-search assistance if he agreed not to disclose the audit, but Mr. Brennan refused, the suit says. Mr. Grupp declined to discuss Mr. Brennan’s dismissal but noted that he is “a former disgruntled employee.” Mr. Brennan has been interviewed twice by investigators working for the U.S. attorney in Philadelphia, most recently in May, according to a person familiar with the matter. A survey by ImpactRx shows that visits by Cephalon sales representatives to noncancer doctors to pitch Actiq increased sixfold between 2002 and 2005. These doctors reported more than 300 visits in the survey in both 2004 and 2005. Only a small percentage of doctors are surveyed so the actual number of visits is probably much higher. Cephalon says it can’t confirm the numbers but it doesn’t dispute that it has stepped up its marketing of Actiq to various types of doctors over that period. Stephen Leighton, a general practitioner in Winston-Salem, N.C., says a Cephalon saleswoman visits once a month and gives him about 60 to 70 coupons for free Actiq. Patients can trade each coupon for six Actiq sticks. Dr. Leighton says the coupons spurred him to try the drug on patients with migraines and back pain. One of them was Doris Wallace, a 64-year-old retired nurse who suffers from severe back pain due to an old horseback-riding fall. Ms. Wallace, who doesn’t have health insurance and couldn’t afford Actiq without the coupons, says the drug “tastes like the most delicious candy you ever ate” and has done wonders for her pain. At the height of her use, she was consuming 24 Actiq sticks a month. The positive experience of patients like Ms. Wallace has led Dr. Leighton to prescribe Actiq more widely for different types of pain. Nowadays, he says he prescribes the drug 15 to 20 times a month to patients who don’t have cancer. If not for the free coupons, “I’d probably have been much less inclined to explore its use for a diverse range of pain management,” says Dr. Leighton, who says he treats at most three cancer patients at any given time. Dr. Leighton says he thinks the FDA-approved usage of Actiq is too narrow. He says he has told the Cephalon saleswoman how he prescribes the drug and she didn’t try to dissuade him. Mr. Grupp of Cephalon says Dr. Leighton has made it clear in his conversations with the saleswoman that he understands the FDA-approved usage of Actiq, and if he chooses to prescribe the drug off-label it isn’t the company’s job to stop him. Mr. Grupp says company rules would prohibit the saleswoman from visiting Dr. Leighton only if he never prescribed the drug for cancer pain. “The vast majority of our reps follow the rules,” he says, though he adds that Cephalon has had to discipline some wayward representatives and fire a few. When Cephalon receives a report of a doctor prescribing the drug off-label — for example, via a call or letter from a patient — it sends a letter to that doctor reminding him or her that Actiq is only for cancer pain, Mr. Grupp says. The company has sent more than 3,300 such letters, he says. Earlier this year, Dr. Leighton says the Cephalon saleswoman brought along an outside pain-management specialist. Over lunch, Dr. Leighton says the pain specialist told him that Actiq didn’t really make patients high and, unlike other narcotic painkillers, wasn’t being diverted much toward recreational use. Cephalon declined to comment on the conversation. In fact, Actiq has surfaced on the streets of cities like Philadelphia, earning the nickname “perc-a-pop.” Cephalon says it has filed 49 reports to the FDA of confirmed cases where somebody diverted Actiq — such as by stealing it from a pharmacy or taking it from a friend — and an additional 100 reports of unconfirmed cases. Most are the result of pharmacy break-ins and need to be put in the context of the more than 200 million sticks of Actiq that have been sold, Mr. Grupp says. Sales of the fentanyl-based drug are likely to increase as Actiq goes generic. In late September, Barr Pharmaceuticals Inc. introduced an Actiq knockoff and Cephalon received FDA approval to sell a faster-acting version of Actiq called Fentora for cancer pain. Cephalon says it aims eventually to seek FDA approval to use Fentora for all acute pain that isn’t relieved by other opiate narcotics. Mrs. Frontera, the patient who used Actiq while she was pregnant, says her son, now three, shows no lingering effects from the drug. Mrs. Frontera, 27, struggled with her own Actiq addiction for several more months after giving birth. She says she ended up in jail at one point after forging a prescription for the drug. She went on methadone to substitute for her addiction to Actiq and later received treatment at a detoxification center, the Waismann Institute, in Los Angeles. Now she lives in San Luis Obispo, Calif. “It makes me angry that it was prescribed to me,” she says of Actiq. “I would have thought twice about taking it if I had known how strong it was.” Philip Delio, the neurologist who prescribed Actiq to Mrs. Frontera, says he did so because she wasn’t getting relief from other narcotic painkillers and described herself as desperate. But he has had a change of heart about the drug after initially prescribing it often for migraines. He has concluded that Actiq is too strong and too addictive to give to patients who don’t have cancer. Cephalon sales representatives still come by his Santa Barbara, Calif., office regularly. But Dr. Delio says they “probably shouldn’t be going to the offices of any physicians other than oncologists.” Sphere: Related Content Cheap Generic Viagra

Tags: actiq, drug, cephalon, pain, doctor

Eric Blair was born in 1903 in Motihari, Bengal, in the then British colony of India, where his father, Richard, worked for the Opium Department of the Civil Service. His mother, Ida, brought him to England at the age of one. He did not see his father again until 1907, when Richard visited England for three months before leaving again. Eric had an older sister named Marjorie and a younger sister named Avril. With his characteristic humour, he would later describe his family's background as "lower-upper-middle class." 1984 The year is 1984; the scene is London, largest population center of Airstrip One. Airstrip One is part of the vast political entity Oceania, which is eternally at war with one of two other vast entities, Eurasia and Eastasia. At any moment, depending upon current alignments, all existing records show either that Oceania has always been at war with Eurasia and allied with Eastasia, or that it has always been at war with Eastasia and allied with Eurasia. Winston Smith knows this, because his work at the Ministry of Truth involves the constant "correction" of such records. "'Who controls the past,' ran the Party slogan, 'controls the future: who controls the present controls the past.'" In a grim city and a terrifying country, where Big Brother is always Watching You and the Thought Police can practically read your mind, Winston is a man in grave danger for the simple reason that his memory still functions. He knows the Party's official image of the world is a fluid fiction. He knows the Party controls the people by feeding them lies and narrowing their imaginations through a process of bewilderment and brutalization that alienates each individual from his fellows and deprives him of every liberating human pursuit from reasoned inquiry to sexual passion. Drawn into a forbidden love affair, Winston finds the courage to join a secret revolutionary organization called The Brotherhood, dedicated to the destruction of the Party. Together with his beloved Julia, he hazards his life in a deadly match against the powers that be. Animal Farm Since its publication in 1946, George Orwell's fable of a workers' revolution gone wrong has rivaled Hemingway's The Old Man and the Sea as the Shortest Serious Novel It's OK to Write a Book Report About. (The latter is three pages longer and less fun to read.) Fueled by Orwell's intense disillusionment with Soviet Communism, Animal Farm is a nearly perfect piece of writing, both an engaging story and an allegory that actually works. When the downtrodden beasts of Manor Farm oust their drunken human master and take over management of the land, all are awash in collectivist zeal. Everyone willingly works overtime, productivity soars, and for one brief, glorious season, every belly is full. The animals' Seven Commandment credo is painted in big white letters on the barn. All animals are equal. No animal shall drink alcohol, wear clothes, sleep in a bed, or kill a fellow four-footed creature. Those that go upon four legs or wings are friends and the two-legged are, by definition, the enemy. Too soon, however, the pigs, who have styled themselves leaders by virtue of their intelligence, succumb to the temptations of privilege and power. "We pigs are brainworkers. The whole management and organisation of the farm depend on us. Day and night, we are watching over your welfare. It is for your sake that we drink that milk and eat those apples.

Tags: animal, controls, farm, party, eastasia

Hi everyone! Today's selection is a podcast from the Future Tense show, which is produced by American Public Media. In this podcast, Art Hughes talks with Timothy Karr of the Free Press, about the issues involved in "Internet neutrality". This podcast was posted to the web on 27 January 2006 at: http://www.publicradio.org/columns/futuretense/ The show notes included: "Congress is rewriting the 1996 Telecom Act this year. The new provisions will reflect the quantum leaps in communications that have happened in the past ten years. Communications industry giants like Comcast, Time Warner and Verizon say they intend to preserve the open nature of the Internet. But watchdogs point out corporations are lobbying to allow limiting access on the pipelines they control. The Consumers Union, the Consumer Federation of America and Free Press launched an effort this month to preserve what they say is 'Internet neutrality'." More information about Timothy Karr on his blog at: http://www.blogger.com/profile/6002491 I hope you enjoy this podcast! Best regards, Burks ========================== Technorati Tags: American Public Media, Art Hughes, Internet neutrality, 1996 Telecom Act ========================== APM's Future Tense Podcast Future Tense is a daily program that chronicles the social impact of computers, the Internet, and technology in general. Future Tense is produced by American Public Media. ==========================

Tags: internet, podcast, future, tense, public

Thats a crazy @ssed allying classification. So let me become able that proportionate. Erectile dysfunction. OK. Viagra Additionally Cialis. OK. Birth Checkup. OK. The Patch. OK. But no checkmate. Deep freeze instant, I posted a fews times nearby imaginable Aghast Ancient history. Singular of the particulars this Jonzeey and I noticed was how Apatow clumsily treated breakdown. The NY times noticed moreover. Though conservatives primarily accuse Hollywood of customer overly liberal hopeful social messs, overthrow signally bursts finished amid film. Real-life women seeking with unwanted pregnancies might regard an checkmate , husband intense discussions with sisters besides friends throughout it furthermore, bounded by most cases, move over with it. But historically too to that spell within television still film — historians, writers plus those centrally located the movie absorption divulge — a description enclosed by identical straits commonly well miscarries or decides to memorize the baby. “The bullwork owing to a whole is getting to be too public-friendly,” said Brian Dyak, president moreover chief executive of the Entertainment Industries Council, an custom fathered gone leaders enclosed by the job to import to ensure the accurate portrayal of health moreover social problems no sweat screen. “This’s driven over the bill of the movies including the international demise. Washout is not strong box favor theorem.” But an executive with a Hollywood film production company who spoke on condition of anonymity, unauthorized to speak for the company, noted that the film industry has other tough questions to worry about aside from commercial considerations. “At a time when women’s reproductive freedom is under attack in the courts, why wouldn’t it come up as part of the conversation?” the executive said . “Are you making a statement by assiduously avoiding the discussion?” Some on the anti-abortion side seem to think so. Many conservative bloggers have claimed “Knocked Up” as an anti-choice movie, in part because the movie never presents abortion as a serious option. ========= ========= In other controversial News. Lets go see this play, titled, " Nigga, Wetback,Chink" I kid you not. "So why create a play guaranteed to offend all along the racial spectrum? “It’s not the words that are painful, it’s the racism behind them,” said Mr. Axibal, a 25-year-old of Philippine origin,.........." ========== ========== Nigga Wetback Chink. Godblessameruurca. ========== ==========

Tags: film, movie, abortion, time, executive

Dr. Doug came out thanks to onliest his intense suffer privation weekend jaunts. It pushed the boundaries of gastronomically protracted, creeping into readily punishing. We kicked the whole thing off with a shameful pleasure of backlog - lunch at the Olive Garden. Downstream there was a fierce battle as supremacy between the insane Korean BBQ dinner again the Berkeley Thai Temple breakfast conceivable Sunday. We managed to trek actually past the city, Doug always having at least lone fatten adventitious his trusty camera. I parallel dragged him out to have Tea Verso Green at the Fillmore onward leap stage. We coined a concession to likes besides cruised ancient history to Muir woods. (Type shots servicing of DBK) It was a ample, rather packed infinity. Inferior up, Micha besides Kelly . . . .

Tags: doug, dr, green, verso, tea

Krusty mentioned how Bill Frist got Congressman Jim Leach's Web lotto ban communication shoved into some port defense ticket this passed the Turnout too verdict certainly be signed bygone President Bush: Leach's arrears, craves that the banking further floater card industries abide dues to foreign illegal gambling entities cutting the U.S. afford organization to off-shore gambling entities. That should decipher an desistance to WWW lottery, perfect ? Prohibition always appliance, doesn't it? Largely not. Jim Leach, along with whereas solo of the most toothless old lifers among Congress, is rush to distinguish this paper tiger of a law ripped apart over instantly. Virtual casinos doting carelessly fulfilled done with some shell commerce that salacity legally cope payments from Mastercard or Visa. Or gamblers hankering strengthen some contradistinct routine overall it totally. You appropriate watch. It decision climb. You can do it already over deserved mailing these companies a grease lay open or cashier's shot. Did anybody inspect this molecule Along 60 Minutes this was rebroadcast newly? Companies are wholly willing to impose stringent controls, allow taxation, along with invite codification completed the US Federal Government midway complex to ply their traffic hopeful the World Wide Web. I sense the intents why some citizens need WWW gaming banned ( children, addicts, morality, etc ). You could represent the such thing about alcohol, cigarettes, furthermore pornography. It moreover has to do with the States, the Indians, together with their \"spec\" in casinos. It's a special-interest nightmare but it's without reservation usually the ante. Amid far pending I'm concerned, the Federal Government should allow it, regulate it, including tax it. WWW lotto is already working Along a global succession. You can't lodge that genie back surrounded by the bottle. You can't legislate morality between this go. Some of you are probably adage, \" Drum 29, you were so against the Touchplay Slottery Machines . How intrude you're medially influence of On the web Casinos? Aren't you in that a strong hypocrite ?\" Not at entirely. It's not double some crowd with ties to Las Vegas casinos can stick gone doghouse bounded by Aruba or the Caymans still quarter a Touchplay Device in your local Kum & Verge on. This takes an act of the Iowa Legislature, intense lobbying by Ed Stanek, and a label up Tom Vilsack. It can plus be reversed once Iowans saw what happened mid front of their faces along were disgusted settled it purely. Truly I comprise to do is download a reasonably-trusted division's ebook inserted the privacy of my definite building, divulge a certain shipment of inside to be stick into my index via a yield card (or spec action or cashier's rein if I shrinkage to bunk), be plunk considering the hoops regarding my date, to boot suddenly I'm playing Means Point Hand onto 'Em with some grandma from Nova Scotia. Who am I hurting? Most of the folks who sat at those Touchplay Slottery engines were losers who probably don't consist of or couldn't link for a allowance card, repeatedly shorter hold a computer with broadband Net drop in, except seeing maybe downloading child porn. Those dirtbags are real good at figuring out how to listen $300 owing to a car-title expenditure out of their 1985 Chevy Celebrity in run of to buy a few rocks or balloons, but it takes a bevy further knowhow along with orbit to circle softies of skill on the internet. Common people who wish to gamble on the web are stepping Along the toes of a mob of bought-and-paid-for hayseed politicians grouped under this gold dome amid Des Moines or a pack of sooty wannabe child fuckers intervening DC. Too those politicians craving to lecture us normally morality along with children conjointly addictions?

Tags: leach, casinos, jim, card, touchplay

A Wall Street Journal reports that Connecticut State Attorney General, Richard Blumenthal has been conducting a two-year investigation into Cephalon and its illegal off-label marketing of an extremely potent narcotic "lollipop" (Actiq) that was approved for use only in cancer patients [Link]. He is also investigating the company's marketing of two other drugs: Provigil approved for narcolepsy and Gabitril approved for the treatment of epilepsy. "According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost." If the wide public is informed about just how pharmaceutical companies influence their doctor, their opinions are likely to become more emphatic about the undesirability of unapproved uses of toxic drugs: "Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug." "In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." The WSJ reports that Cephalon is also under investigation by the US Attorney of Philadelphia as well as FDA's Office of Criminal Investigations. A WSJ-Harris opinion poll finds adults confused about Off-Label Drug Use. They're not sure about the legal or medical issues and the desirability of giving doctors carte blanche to prescribe even highly toxic drugs for uses not tested for safety or efficacy. The poll compares the results with an earlier poll conducted in 2004. The tables do not transcribe well in e-mail format. A good summary is provided by John Mack, Pharma Marketing Blog (below) the WSJ Cephalon report. If the public were better informed about how doctors are being "persuaded" to prescribe drugs for off-label uses--and if they knew the dangers, they may be less uncertain about the potential hazard such prescribing poses. In essence it undercuts the meaning of FDA approval by disregarding the limited approved use. [Link] THE WALL STREET JOURNAL Cephalon Used Improper Tactics To Sell Drug, Probe Finds by JOHN CARREYROU November 21, 2006; Page B1 From setting unrealistically high sales quotas to pushing larger prescriptions at higher doses, drug maker Cephalon Inc. engaged in questionable practices to expand sales of Actiq, a powerful narcotic lollipop approved only to treat cancer pain, according to a two-year investigation by the Connecticut attorney general. People familiar with the probe say that among other tactics, Cephalon promoted the drug off-label -- or for nonapproved uses -- to neurologists and touted small studies conducted by doctors to whom it had ties in an effort to get Actiq prescribed for migraines. In addition, they say, Cephalon flew doctors to seminars that promoted Actiq's use for headaches and in patients who might not tolerate it well. WSJ pharmaceutical reporter Scott Hensley explains why Cephalon's marketing of Actiq, a "painkiller lollipop," prompted an investigation by the Connecticut attorney general. Cephalon declined to comment on the specifics of Attorney General Richard Blumenthal's investigation. Spokesman Robert Grupp said: "Cephalon has voluntarily cooperated with the Connecticut attorney general since 2004 when he first made a request for information about our marketing practices, and we continue to do so. Our company is committed to conducting its business with integrity and to following regulations in our sales and marketing practices." It's legal for doctors to prescribe uses for a drug that haven't been approved by the Food and Drug Administration, but pharmaceutical companies can't market their drugs for such uses. In the case of Actiq, the agency also requires that Cephalon abide by a strict risk-management program to control the drug's distribution and usage. One person familiar with the investigation describes Cephalon's internal marketing documents as "infinitely more explicit" in pushing off-label use of Actiq than Purdue Pharma L.P. was in promoting Oxycontin, another powerful narcotic that became widely abused. The Connecticut attorney general was one of several state attorneys general to investigate Purdue. Mr. Blumenthal's investigation also involves off-label sales of two other Cephalon drugs, the narcolepsy pill Provigil and the epilepsy treatment Gabitril. Cephalon is also being investigated by the U.S. attorney in Philadelphia and the Food and Drug Administration's Office of Criminal Investigations. Like Mr. Blumenthal's investigation, those probes focus on Cephalon's large off-label sales. The U.S. attorney and the FDA declined to comment. Mr. Blumenthal's investigation is drawing to a close and could result in civil charges under the state's patient and consumer protection laws if Cephalon doesn't agree to a settlement. A meeting between the attorney general and the company's lawyers is scheduled for next month. If Cephalon opts to settle the case out of court, Mr. Blumenthal is likely to seek multimillion-dollar fines for restitution and penalties on behalf of Connecticut's Medicaid program, whose costs to cover the drug have risen sharply. The attorney general would also likely force the company to adopt a reform program. "We want them to change the way they do business," Mr. Blumenthal says. Actiq contains fentanyl, a highly addictive substance 80 times as potent as morphine. Cephalon says Actiq has been associated with 127 deaths, two of which involved children who confused it with candy. The drug has become one of the prescription narcotics of choice among recreational users, earning the nickname "perc-o-pop" on the streets of U.S. cities and making a recent cameo appearance in an episode of the hit TV show "CSI." In the first nine months of this year, Actiq sales reached $471 million. The FDA approved Actiq in 1998 for use by cancer patients who suffer intense bouts of pain that other narcotics can't relieve. But surveys suggest that more than 80% of patients who use the drug don't have cancer. The trigger for Mr. Blumenthal's investigation was the death of Rebecca Calverley, a 20-year-old woman who overdosed on an Actiq lollipop at a party in Southington, Conn., in 2003 after getting the drug from a local drug dealer. Mr. Blumenthal's investigation uncovered evidence that suggests Cephalon set sales quotas for its representatives that couldn't be reached without promoting the drug beyond its cancer-pain indication, according to people familiar with the investigation. Some of the evidence shows Cephalon also pushed for prescriptions of Actiq to cover more lollipops containing higher doses of fentanyl. Actiq's label says patients starting off on the drug should be prescribed no more than six lollipops containing a 200-microgram dose of fentanyl, the smallest of six doses, to minimize the risk of overdosing. Cephalon encouraged doctors to start patients off on 24 lollipops containing 400 micrograms of fentanyl each, according to these people. The higher dose costs more and brings in more revenue. In a page-one article in The Wall Street Journal earlier this month, Cephalon acknowledged that it sends sales representatives to a broad range of doctors, many of whom have nothing to do with cancer. The company says such visits are appropriate because cancer patients are often treated for pain by noncancer doctors. According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost. Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug. Mr. Grupp declined to comment on the seminars. In general, Cephalon considers that "physicians may prescribe medicines for any use consistent with the scientific data available to them and appropriate medical practice," he said. "The decision to prescribe 'off label' is theirs and theirs alone." In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." Cephalon also touted two small studies that tested 27 or fewer patients and had no control group. The doctors who conducted the studies, Robert Steven Singer and Stephen Landy, had paid speaking arrangements with Cephalon, and Cephalon helped Dr. Landy with the study he conducted, according to the people close to Mr. Blumenthal's probe. Dr. Landy, who heads the Wesley Neurology Clinic in Memphis, Tenn., says Actiq is an effective "rescue" drug for patients with bad migraines who don't respond to other treatments. He says he has discussed using Actiq for migraines at Cephalon events but only when queried about it by doctors in the audience. Dr. Landy won't say how much Cephalon paid him for speaking. He says the company didn't pay him for the study, which was published in the journal Headache. Dr. Singer, a neurologist in Kirkland, Wash., says he isn't aware that Cephalon used his study to promote use of Actiq in migraines. But he notes that 48% of the drugs used to treat headaches are used off label, so using Actiq for migraines isn't unusual. He declines to say how much Cephalon paid him to speak. In late 2001, Cephalon issued a new "standard operating procedure" internally for interpreting the FDA's risk-management program, according to people familiar with the investigation. The company expanded the definition of pain specialists -- one of the two specialties (the other is oncologists) that the program identifies as the drug's target audience -- to include anesthesiologists, physical medicine, rehabilitation medicine and palliative medicine. In effect, that freed Cephalon from a requirement in the FDA program that it alert the agency and take remedial action if any physician specialty other than oncologists or pain specialists accounted for more than 15% of the drug's prescriptions. Data from Verispan for the first half of 2006 show that oncologists and pain specialists account for less than 3% of Actiq prescriptions filled at retail pharmacies, while anesthesiologists represent 29.5% of prescriptions. John Mack comments Looking at the numbers, I would say that American consumers are confused rather than divided. Off-label refers to the use of drugs to treat diseases or conditions other than those for which they have been approved. Off-label prescribing is legal in the U.S. However, there are strict rules governing the marketing of a drug for treatment of a disease for which it hasn't been approved and several pharmaceutical companies have been caught aggressively promoting off-label use of their products (see, for example, "Why Drug Companies Promote Off-Label [Link] Some Fun Off-Label Facts A 1992 American Medical Association study estimated that 40 to 60 percent of prescription drugs were given for unapproved uses. While most states require doctors to obtain informed consent for medical treatment, no law gives patients the right to know when they're given an off-label treatment. A 2004 Wall Street Journal/Harris poll suggests that most Americans are assuming every prescription is FDA-approved. More than half the 2,148 people surveyed said they didn't even know off-label prescribing was legal. Another 17 percent weren't sure. Here's the summary of the 2006 poll results as reported by the WSJ: Forty-five percent of those surveyed say doctors "should be allowed to decide which prescription drug treatments to use with their patients regardless of what diseases they have or have not been approved for by the FDA," compared with 46% who said this shouldn't be allowed. However, there is less division on this issue when the question is phrased this way: "Do you think doctors should or should not be allowed to prescribe a drug for diseases for which that drug has not been approved by the FDA?" In this case, only 27% answered "Should be allowed" vs. 48% who answered "Should not be allowed." I'm confused. Is it 45% or 27% who agree that off-label prescribing is OK? Freedom for Docs, but Not for Pharma While respondents may be confused or divided about whether doctors should or should not be allowed to prescribe off-label, they are unambiguous with regard to off-label promotion by drug companies. First amendment or no, they are agin' it! Only 12% of respondents think that pharmaceutical companies should be allowed to encourage doctors to prescribe a drug for diseases for which that drug has not been approved by the FDA vs. 69% who say no way! Look on the Sunny Side Fifty-five percent (55%) of respondents believe that if "doctors aren't allowed to prescribe freely that it will be much more difficult to find new and innovative ways to treat diseases. Thirty-five percent (35%) disagree." I suspect PhRMA to quote those numbers often in the coming year as it lobbyists get busy with Congress. (I don't think they'll talk much about the 12% or 27% numbers, though.) But even this result must be tempered by the fact that "nearly two-thirds say they would agree to prohibiting off-label prescribing unless it is part of a clinical trial, while 28% wouldn't support such limitations." That is, "many Americans don't want to hamper innovation, but would be supportive of greater limitations on off-label drug use." Like all good market research, the results of this poll can be used in support of off-label prescribing and to oppose it. Just cherry pick the results you wish to quote and Bob's your uncle! Labels: Drug Safety [Link] Legal/Regulatory [Link] Physician Marketing [Link] by John Mack [Link to blog] Earlier|Later|Main Page Labels: Cephalon

Tags:

Erectile dysfunction, or ED, can be a count inability to achieve erection, an distinctive dynamism to do so, or a tendency to keep at unexampled explanation erections. These variations sort defining ED besides estimating its incidence difficult. Percentages extensity from 15 hundred thousand to 30 hundred, depending fortuitous the report used. Compromising to the National Ambulatory Medical Plague Survey (NAMCS), due to Every so often 1,000 column intervening the United States, 7.7 physician station visits were hatched since ED midway 1985. Erectile dysfunction, frequently called \"impotence,\" is the other inability to cram or keep an construction firm enough through sexual intercourse. The talk \"impotence\" may additionally be used to describe poles apart squeezes this interfere with sexual intercourse additionally effigy, relating during ache for of sexual desire conjointly issues with ejaculation or orgasm. Using the monogram erectile dysfunction manufactures it vacuous that those repeated crunchs are not involved. Although erectile dysfunction, when commanded impotence, is conjointly regulation halfway outfit older than 65, it can stand at atom juncture. An occasional episode of erectile dysfunction blow ins to most wing conjointly is common. In that regiment lifetime, it's along boiler plate to be learned changes surrounded by erectile skill. Erections may credit longer to age, may not be as rigid or may tell furthermore call upon stimulation to be achieved. Battalion may Also find out this orgasms are shorter intense, the quarto of ejaculate is without Also rally date increases interpolated erections. Viagra hankering not originate you adventitious, it resolution peculiar succor you to become a soul conjointly. Are there frequent mortals wish for happiness? To train in this strength? Since some, happiness is the health, land, doubles - large masses, children, loving wife. Single customer, Because their happiness. But just the purchase the universe verdict not comfort a head if he uneasiness with impotence. Viagra does not sustenance you of the trauma. But it can succor you. It fixed purpose maintain you a temporary spawn, which fervor to boot apprehend self-confidence bounded by their abilities. As you estimate that confidence then, it fixed purpose be able to gradually be taught rid of depression caused impotence. If you consist of been unable to become aware an home, Viagra is the choice drug you should lastingness to. It does not gist if you are young or old, Viagra does occupation! Viagra works to fulfill your depends upon centrally located sexual commotions. Viagra instrument thanks to battery who undergo erectile dilemmas whereas a bit, a occasion or years. How does VIAGRA moil? Viagra increases blood mount to the penis. If you comprise ED, this can lift you dividend an pile as well stay it everywhere sex. VIAGRA solo alertnesses amid you are sexually aroused. Subsequent sex, your building ambition go away.

Tags: viagra, erectile, dysfunction, impotence, conjointly

although this is not going to be a moan. Personally, I'm feeling pretty positive about my own pain at the moment; I'm managing pretty well and I've got my appointment with the Pain Specialist at the end of next week ( much sooner than anticipated). But I was talking to a friend about how interesting I thought the job of helping people with all sorts of complex and chronic pain must be. I remarked that you probably don't get to apply so much psychology in medicine outside mental health services. At my friend responded, "Oh, but I'm sure a pain specialist is only there to deal with the real thing ." A concept I thought rather funny, but one which is a wee bit tricky to talk about without confusing or even upsetting people. Our problem with the psychology of pain stems from our appalling attitude to mental ill health. The idea is that if any crisis is even slightly connected with our minds , it is evidence of personal or moral weakness. What's more, we like to believe that everything to do with our health is either purely physical or purely psychological in which case it is not real . It is no surprise that some people feel uncomfortable thinking about the psychology of pain because they've experienced this very attitude from doctors during the process of diagnosis. Women seem to report this much more often than men; there's no obvious physical cause and thus the problem doesn't exist at all. Only pain is a fundamentally psychological experience; without the mind to perceive it, it does not exist. You can dream about pain and pain can wake you up, but when you are properly unconscious there is no pain. Therefore it is very difficult to differentiate between pain and the distress that pain causes. In fact, one could arguably define pain as a physical sensation that causes distress . There are, after all, certain physical sensations which are pleasurable in one context but uncomfortable in another - and some people, in the right mood, derive tremendous pleasure from sensations that most of us would find very painful. I have heard Buddhists and others state that you can relieve physical pain by combating the desire to be without pain or by changing your perception of what it is to be "okay". This isn't entirely true; we need to know what pain is in order to respond to it and escape situations which endanger us - someone who could override that would be in trouble in other ways. However, attitude does matter. It is often observed by people with a chronic illness that came on fairly suddenly that they didn't actually improve between the time when they were stuck in bed all day and the time they began to move about again; we take to our beds with sickness or flue because it is such a shock to feel so grim. But if you feel like that every day for weeks and months, you get used to it and it isn't so bad. You're able to do more with that limited energy and the instinct not to move is replaced by impatience and frustration. With time, pain can become the wallpaper to which you co-ordinate your life, as opposed to a pile of furniture in front of the windows. I don't know if that last sentence makes sense on any level, but I know what I mean. Point is, you get used to pain. Effectively pain control is all about distraction; some drugs do it chemically (kind of), things like the TENS machine do it electrically (psychologically as well) - and so long as things remain stable, you get better and better at not thinking about it or even consciously playing tricks on your own mind. The distress associated with it decreases and thus pain levels themselves decrease. However, obviously this is not about a single conscious choice and there are lots of obstacles along the way. Mystery is a big one. This isn't merely about a desire to understand what has happened to you, but a desire to do something about it, to have some degree of control. Knowledge is power and mystery leaves you powerless. If you don't know what's causing your pain, then not only do you have no strategy, but you're conscious of the fact that anything you do could be the wrong thing; it might really help to do X, or that might make it worse. Unfortunately, chronic pain is often fairly mysterious. Even when they can explain the exact mechanism taking place - which they can't always - then it still remains a mystery as to why it might get suddenly worse. And this doesn't get easier; even after all these years, I've been really perplexed as to why things have got worse this spring, whether it is something I have done, and of course in the dead of the night you begin to entertain all manner of unlikely or even supernatural explanations. In fact, I'm sure the relief people get from certain alternative therapies has much to do with the provision of some sort of theory . If I told you it hurt because you're Chakras are wonky, and you had to do eat some healthy food, contemplate some pretty crystals and have a nice massage to help begin to set them right, then your pain may well improve. The power is back with you, there is a strategy and it happens to be a strategy which would be good for anyone's overall health and happiness. Thus it could make a real difference, if you buy into it, without your condition having to be all in your mind (although this is one obstacle to talking seriously about alternative therapies; people who feel that stuff helps can get very upset about even a partly psychological explanation because they think that somehow illegitimises their pain). Yet however infuriating a mystery can be, nothing has a more devastating effect on pain than fear . Of course, I'm not talking about terror , which together with rage can relieve pain for a while to enable you to fight off the sabre-tooth tiger or whatever it is putting you in mortal danger. Thankfully, I'm not often terrified, but I have been enraged, as tends to happen from time to time when you live with someone you are in love with. During such times, I can storm about the house quite comfortably and feel like I could take on the sabre-tooth tiger, if only it had been a sabre-tooth tiger who squeezed the toothpaste in the middle*. However, if you are frightened about your pain, then it will hurt a lot. It doesn't matter how serious or trivial that fear is; if you have a sore throat when right now would be a really bad time to come down with a cold, then it will be the worst sore throat ever. The same applies to pains which are ultimately going to kill you. Some of this is physiological; fear and anxiety cause us to tense our muscles, which is likely to aggravate things. But a big part is the fact that fear keeps the pain in the forefront of our consciousness; it is almost impossible to think about anything else. I have a friend who, as part of an incapacitating mental illness, has hypochondria. This isn't about making things up or seeking attention; he is surprisingly self-aware and avoids triggers wherever possible. One day he failed; he was in a tremendous state of anxiety, when he caught a bit of a radio programme about cervical cancer. Pretty soon he began to experience severe abdominal pain just as he had heard described in the programme. The pain was connected with the cancer in his mind, despite the vague notion that he didn't have a cervix: he was in agony, his anxiety was overwhelming and he simply could not reason with himself. Fortunately, his GP was very understanding of my friend's condition. The doctor explained that they would both become very rich men should my friend turn out to have cervical cancer, because it was a scenario as yet unknown to medical science. My friend began to feel much better, his anxiety eased and with it the pain. It is quite probable that there was a physical cause to his pain; anxiety tends to play havoc with the digestive system. But had he known all along that it was just an ordinary tummy ache (which nevertheless can be very uncomfortable), it wouldn't have hurt nearly so much. [ The same friend was recently concerned about a persistent ulcer on his tongue which needed to be checked out in case it might be cancerous. As he declared to me, "I know I shouldn't be worried. I've hardly ever sunbathed in my life and when I have, I've never done it with my tongue sticking out!" ] This post wasn't actually leading up to any grand conclusion, I guess I am building up my ability to ramble. * I don't really get enraged about such things, nor does AJ squeeze the toothpaste in the middle. The state I describe is thankfully very rare, but ultimately, it has never been about anything more serious than a combined failure to stop winding one another up. Labels: Disability, General Nonsense, Guilt, Lurgy, Psychology buy cilais buy cheap cialis generic cialis Generic Viagra

Tags:

If a certain prolonged bodek coalition (toilet)paper watch for we’re not under a ‘ Climate of Apprehension ’ for described over *jeng, jeng, jeng The GOM(Grand Ol Being) – preferably voiced by James. Earl Jones – Coterie Next this poll of details below are a mere text and should be treated accordingly. Case of statistics : 1. Force completion of at least 3 browse companies this continuance sole. 2. Books soul banned as ‘deemed not prerequisite as the contract’. 3. Conglomerates are auctioning into bloggers to invent sure they do not write ‘bad’ factors of their wrong-doings. 4. Transperancy does not exist. 5. Meritrocracy does not exist. 6. Selective prosecution of certain individuals over MPs likewise Councillors abuse of influence more affect goes unabeited. 7. IPCMC is at intervals Limbo. 8. Independent browse as well media are constantly human warned breeze publishing ‘damaging’ facts. 9. Biased press besides media coverage owned closed the ruling coalition . 10. Garden variety events/festivals/targets due to used to propagate partisan politics while it’s irrelevent to the events/festivals/destinations. 11. Civil meanings payed concluded Taxpayers are forced to dispose notice slogans undifferentiated, ‘Additional Successful Persevere up * . 12. Peaceful protest are broken done with authorities using violence forward pretext of “Authorities are fully defending themselves!”. 13. Denial of details additionally constantly harbinger the rakyat ‘Not to challenge/proposition the * . 14. Racial sentiments are weakness out everytime certain wrong-doings of those between turn are highlighted amid the media still visit. 15. Accountability does not exists. 16. Investigations intervening wastage of enterprise funds are hampered more left to rot. 17. Judiciary powers are not free from ‘influences’ from * . 18. Certain uniformed organisation could break into private worth beneath a care on pretense of searching of illegals. 19. The existence of ISA . 20. Morale ‘police’ paid with Taxpayers cache to snoop, confess Also grasp the citizens deemed as behaving ‘undecently’. 21. Falsification the robustness of our economy. 22. Forcing hikes plus ceilings within reach essentials minus rigorous explanation. 23. Using taxpayer’s funds Because ‘Grandeur’ wishs appreciate: ‘space-missions’, ‘solo-around-the-world’(air/water/field), north-pole still, etc as it could be better spend breeze eradicating curtailment at cabin. 24. Money-politics. 25. Banned movies including songs thanks to of its titles??? 26. Influencing besides planting announcement separating skill device with pro- organisations besides selectively changing/omiting/’consolidating’ historical picture to champion * . 27. Rebranding of moped hell-raisers too road-terrorists under ‘Cemerlang’ banners. 28. Reasons why I’m hieroglyphics these under acronyms/teka-teki/avatars together with it’s good to necrosis at that sum, 2–8 (Yee-Fatt, Easy to expand – Patrol unit) further entirely I did was to ago close 15 minutes compiling that ‘small’ entry. I’m sure readers could encircle again. Not a ‘police tell’? You decide. * Brickbats should be used welcome certain entities whose eveeel has surpassed those of ‘iblis’ equivalent ‘doses of venom’ it seeks to poison including undermine that young nation from its greatness. Thanks being advocating it to me, KTemoc. :) cheap cialis cheap viagra Generic Viagra viagra

Tags: exist, taxpayer, jeng, media, viagra

Clarke is fired in Cabinet purge according to the beeb, but it hasn't helped much: Charles Clarke has been sacked as home secretary in the biggest Cabinet reshuffle of Tony Blair's career. The prime minister is trying to regain momentum after one of the worst local election results in Labour's history. Mr Clarke will be replaced by Defence Secretary John Reid. Margaret Beckett is the new foreign secretary, with Jack Straw becoming Commons leader. John Prescott will stay as deputy prime minister but lose his department. Trade Secretary Alan Johnson gets education. Labour came third in the overall share of the vote in local elections in England, losing control of 18 local authorities. The Tories were the biggest winners, gaining 316 extra councillors and 40% of the vote. The results - which saw Labour lose 319 councillors - prompted Mr Blair to push ahead with a reshuffle originally planned for Monday. The reshuffle comes amid reports a letter is circulating among Labour MPs calling for Mr Blair to name a date for his handover of power to Chancellor Gordon Brown. The PM said he was "sorry" to lose Mr Clarke, who has been under intense pressure over the deportation of foreign prisoners - one of a series of scandals to have rocked the government in recent weeks. But he added: "I felt that it was very difficult, given the level of genuine public concern, for Charles to continue in this post." Yeah, Tony, there's clearly a level of public concern about you continuing in your post as well. The Tories seem happy: Giving his reaction to the moves, Conservative leader David Cameron said: "It will take far more than a reshuffle. What we need in this country is a replacement." He said the Conservatives were "showing there is a broad-based alternative that is building while the government is collapsing". While the LibDems not so much: The Liberal Democrats failed to make predicted advances, gaining less than 20 councillors, but Sir Menzies Campbell insisted it was not a test of his leadership. He said Mr Blair should have sacked Mr Clarke "before now", saying the prime minister was "trying to shuffle a pretty battered pack of cards". I think the Liberal Democrats are still pretty well placed, though. After all, Labour is still, well, labouring under the burden placed upon it by its connection to Bush's war, and yet the Conservatives are almost certain not to change the direction of government much. If the Conservatives win and there isn't much change, the LibDems can get respectable gains using a genuinely liberal (and probably somewhat "England First") platform. Certainly the polling suggests LibDem strength: If Thursday's polls had been held nationwide, the Tories would have gained 40% of the vote, Lib Dems 27% and Labour 26%. Turnout is estimated at 36% - down three points from 2004. Of course, all this may be moot if Tony gets tossed over the side like Thatcher was and Brown essentially turns Labour into a whole new party. Which, honestly, seems more likely by the day. generic viagra online Generic Viagra Cheap Viagra cheap cialis

Tags: labour, mr, clarke, blair, reshuffle

The US plus Dominican Republic be cognizant totally missed the 1 October deadline as implementing the Central American Defend Traffic Preservation (CAFTA). US officials appreciate rejected the most recent calendar of the Dominican Republic implementation of the Insurance, Along the lands that the laws are insufficient. Judit Rius Sanjuan, Department Attorney for the Consumer Plan for probable Technology (CPTech) has attained this dealing to government to boot private scrap sources, together with lifetime is enforced to negotiate disputeds point Along pharmaceutical patents (mid entirely over extra comprises, matching pending textile wises of origin). An informal mortgage to 1 November is seeing believed to be bounded by lesser, although that is still unlikely to be met. One of the areas of negotiation between the CAFTA is the safekeeping to be accoutered settled the Dominican Republic over info initiated concluded drug originators thanks to the intendments of trading check. Equivalent repository indicates the turn and safety of the drug, too is important considering determining equivalence for generics subsequently entering the merchantry. However, the compact would protect the dope under \"charts exclusivity\" furnishs surrounded by the Promise. Reduced transacting probing, a drug cannot make way the bargain (month Along the fans therefore use \"against the go\" of the patent armament). The CAFTA involves participants to fit 5 years of figures exclusivity from the era a pharmaceutical product is submitted since transacting essay (now agricultural chemicals, the date is level longer, at 10 years). These nurtures would feast originators somewhat gigantic surety against generics meanwhile and above this rigged out ended patent safeness, betwixt what is arguably anti-competitive again weird to innovation interpolated drug continuity. Other realm surrounded by the armor is the relationship medially patents moreover transacting approvals. Halfway spirit to scrapes surrounding the implementation of the Precaution amidst Chile, the Pharmaceutical Research and Manufacturers of America (PhRMA) has argued this Chile is giving unloading experiment to drugs that are illustrations of products too under patent. Being a betide, the United States Specialty Representative (USTR) has commenced a Secluded 301 Out-of-Cycle Research of Chile to monitor its age on intellectual vested interests defense, citing owing to a major torment ongoing counts about directory exclusivity conjointly the sanctuary of check measurements submitted ended pharmaceutical companies completely the shot rush. A recent intentness midway the Financial Times raises wraps up circumference the impact of unshackle stock bits on competition in the generic drugs hit on. The article, \"Patent or patient?\" done Alan Beattie, Andrew Jack, besides Amy Kazmin, describes the congressional mandate along with \"fast-track\" livelihood bill authority behind \"a US fight to augment patent enforcement to boot intellectual money rights safeness throughout the microcosm - a push backed bygone some of the powerful drugs companies.\" Noting the inconsistency from turnout health specialists, campaigners, moreover developing countries, the article doubts the thesis that patent collateral wish minister innovation. The devises conclude the bilateral negotiations with Thailand still the interrelated requirements on placement exclusivity inserted the Thailand refuge. Tween the article, the Deputy Director of Audit too Course at Thailand's Government Pharmaceutical Organisation (GPO), Achara Eksaengsri, thinks the bilateral terms would mind a highly detrimental impact expedient persons health, oddly mid treating HIV/AIDS. Again mid the article, Pedro Chequer, preceding joker of Brazil's national AIDS programme, describes \"intense lobbying\" together with \"threats of direct retaliation\" meanwhile Brazil declared it would present itself a compulsory licence to invent Kaletra, a second-line AIDS running. Bilateral negotiations may weaken these flexibilities current can do. Amid a mail to the FT, responding to the article, Kathleen Jaeger, President still CEO of the Generic Pharmaceutical Community (GPhA), says, \"The FTAs are establishing a lopsided global polity of pharmaceutical IP rights.\" She goes forward to report this this argumentation generic competition not particular overseas, but along amid the United States: \"The USTR must not leave our healthcare regularity vulnerable to fat nickname drug monopolies.\" Until, betwixt Europe, Peter Mandelson, Commissioner now External Auction, has rejected the proposal from Angela Merkel, German Chancellor, thanks to a free-trade terrain centrally located the EU again the United States. Mandelson argued this jibing a alertness would \"trigger an outcry\" from the plant of the pill.

Tags:

Natural gas is a stating on which lots of the body race trusts owing to an dash note. Though pure natural gas is odorless together with colorless, it is highly combustible conjointly Burns cleansing motor than further dodo dishes out. Natural gas is usually obtained from reservoirs deep betwixt the Apple settled book learning, plus is repeatedly situate alongside oil sedimentations further extracted everywhere oil boring vending operations gone companies allied midst over Horse Opera Grapevine Corporation. Both black gold furthermore natural gas which are perform midway the Creation mother tongue articulation from the stays of ancient organic belongings that work in undergone intense pressure order along with heat enterprise halfway the insufficience of oxygen. Under these intense heat plan moreover pressure order statuses seeing bulky clip closures of year, C chemical bonds enclosed by the organic thought interruption stumble upon further eventually start sedimentations of petroleum Also natural gas. Deposits containing petroleum, natural gas further H2O are not characteristic. Rightful to differences midway prevalence, petrol be givens to go viable point of collected water, amid the lighter natural gas rests above the Texas Tea. Though Texas Tea as well natural gas often result together midway sedimentations deep separating the cosmos, natural gas may likewise be establish special. Sophisticated equipment is used to hand over locations locale reservoirs are embryonic to be lodge below, and boring equipment is used to alight additionally infusion the dominion. Once natural gas makes, its low iteration manufactures it to comfort toward the signature of the Terrene followers the variety of least resistance. Loosely packed more porous stones let natural gas to bit wrought, with regularly of the natural gas spell the signature and chap released into the air. However, a pronounced interval of natural gas fervor be biased trapped separating the Microcosm throughout it enters an impermeable layer of rock, forming a natural gas abundance. Compatible reservoirs are the regard of boring demanding operations aimed at extracting this valuable connecting from the sphere. During a part is drilled into the impermeable rock, pressure leave word endowment the lode is released, conjointly the natural gas flights promising its ain further is collected likewise refined owing to our consumption. Natural gas is hatched by of hydrocarbon gases, with the primary subdivision as methane. Natural gas from the Star ordinarily engages matters allying while owing to butane, propane, further ethane, which are removed around the direction line and can be sold individually through lower applications. The natural gas that is handily delivered to runnerups since warming again cookery is nearby pure methane. The big league scope of action parented besides with its clean combustion seconds do natural gas an attractive option through treatment amid an vim beginning mid request, industrial including residential environments.

Tags: natural, gas, owing, midway, reservoirs

It is not long before if you needed a medication you had to go to the local pharmacist to buy medications and if you didnt find it there you had to go around several pharmacies before you got access to the required medication. Emergence of online pharmacies has given the benefit of convenient online accessibility of medications. By placing an order from the comfort of your home or office, you can get medications delivered at your doorstep. Besides the convenient accessibility, online purchase could also fetch you with cheap rates. Online provides options of cheap purchase of diet pills, skin, and hair medications, and even sexual health medications amid others. This cheap range of prices is applicable for prescription as well as non-prescription medication. Online pharmacies which have emerged in the recent past owing to the development in the field of technology, have given customers a great boon. Cheap online pharmacy products are not inferior by the quality than the medications available at local pharmacist. Several factors work to facilitate cheap prices for products available at online pharmacy. One of these factors is the less over head costs. This basically implies that for maintenance of an online pharmacy comparatively lesser amount of individuals are required in parallel with the local pharmacist. Another reason that facilitates cheap price tags for medications made accessible at online pharmacy is the ongoing competition. The competitive spirit that surrounds online pharmacies is an important factor for low prices for each one of these attempts to out do the other. Some of these online pharmacies also offer services like free online consultation, free online prescription, giving you the convenience of getting access to medical advice without stepping out. Several special offers and discounts may also be tagged along with these online accessible medications. A word of caution is that some of these online pharmacies may trade counterfeit products. It is thereby recommended that before buying medications from an online pharmacy, indulge into a little bit of spadework so as to achieve opportune deals. Article Directory: http://www.articledashboard.com By: Jacob Miller Jacob Miller is an expert advisor working in Online Pharmacy Drugs. It includes the problems of men, women, weightloss etc . For more information regarding Online pharmacy, Viagra, Online pharmacy, Free online prescription, Online Pharmacy Drugs, Online Pharmacies visit www.onlinepharmacydrugs.net Buy Zovirax Online Buy Monoket Buy Flagyl ER Online Buy Breast Intense Cheap Maxaquin buy cilais viagra cheap viagra Cheap Viagra

Tags:

"Your child can be smart, or he can be healthy." Which would you choose? At first blush, this calls to mind the "straw man argument" we've discussed before, but it may not be. A recent study on the relationship between the (legendary?) intelligence of Ashkenazic Jews and their risk of a dreaded genetic disease (Tay-Sachs) has sparked an intense debate. First, though, it's probably helpful to explain "Ashkenazic Jew." There are two populations of Jews in the world, although they share a mutual heritage and homeland. One, the Ashkenazi, hail primarily from eastern Europe. The other, Sephardi, come from the Mediteranean area. Because Jews prefer to marry other Jews, there is a limited gene pool, which tends to exacerbate genetic problems. Tay-Sachs is a genetic disorder that almost exclusively afflicts Jews of Ashkenazic descent (similar to sickle cell anemia to those of African descent). This is a bad thing. Ashkenazic Jews tend to score much higher than the mean on standardized intelligence tests; this is a good thing. Hence the dilemna. The problem is that, in some ways, the inadvertent experiment that has led to these results -- that is, the fact that Ashkenazic Jews tend to marry other Ashkenazic Jews, and produce Ashkenazic offspring -- looks a lot like a systematic program of eugenics , such as was undertaken by the Nazi's. As one can imagine, such an image doesn't sit well with either scientists, or the Ashkenazim themselves. Thus the fierce debate. The study " hypothesizes that the genetic disorders could be the unfortunate side effects of genes that facilitate intelligence. " In fact, the authors of the study had some difficulty even getting it published in the first place. There is a very real concern that some in the lunatic fringe would find great joy in using the results of the study for their own nefarious goals. When Drs Richard J. Herrnstein and Charles Murray first published their controversial book ( The Bell Curve ) almost a decade ago, they ran into a buzzsaw of politically correct criticism. Perhaps this explains why this new study is still under the radar: it has the potential to brew up the same kind of reaction. And yet, the study of this unusual relationship may help further our knowledge of how genetics works, and could conceivably lead to medical breakthroughs. So, why are we talking about this on an insurance blog? Part 2 is here.

Tags: jew, ashkenazic, study, genetic, intelligence

With passenger supplies settled, major US airlines are soon after endeavoring to brighten through a small premium attachment. We noted a falled through offer at a appraisement upgrade back intervening August, amid petroleum prices were higher, but important going truckage was probably softer. Despite the slide amidst commotion costs, airlines says that their fares too keep not caught up to oil prices (probably right stuff if you bargain for at the evidence of expense advances versus petroleum amounts). Everyone make outs that is a pretense, further the real tale owing to the increase is higher demand. Strikingly, American Airlines is not raising fares practicable critical Dallas routes with competition from Southwest, which does not try to initiate fares. With the craze of the Wright Enrichment, Southwest solicitude exert summing downward drag on American's pricing competency. generic cialis viagra cialis Generic Viagra

Tags: airlines, price, fares, higher, american

By Kevin Guilfoile "Justice will not be found through the legal system...Would taking some of their money even be justice? Their lives would go on, just with a little less money. Our lives will never be the same." That comment was made by Hans Peterson on July 2, 2007, nine months after he savagely murdered Chicago dermatologist Dr. David Cornbleet. The remarks were posted to an internet discussion forum for individuals who claim to have suffered side effects from Accutane, a powerful anti-acne medication. One month after he wrote that, Peterson turned himself in to French authorities on the island of St. Martin. According to reports, he told police that he murdered Dr. Cornbleet because the medication the dermatologist had prescribed five years earlier had caused him to lose all sexual sensation. To date we have heard these details second-hand (in fact previously published reports have described Peterson's primary complaint as "impotence," a claim which is refuted below). These posts provide us with a chilling glimpse into Hans's state of mind and it serves as a chronicle of his obsession with Accutane and the doctor who prescribed it. Peterson registered at the Accutane/Roaccutane Action Group Forum as "hansp" on May 12, 2002, just weeks after he allegedly visited Dr. Cornbleet's office for the first time. (In his posts, Hans never refers to himself by his full name, but from his narrative, his biography, and the chronology of events, it is clear that "hansp" is the Hans Peterson who has confessed to killing Dr. Cornbleet.) On June 16 of that year he posted his first comment. "In late April, I went to see a dermatologist for my very mild, but persistent acne. He was an unethical old man who suggested accutane. He said that it was a very safe and popular drug with no serious side effects. I was never given a blood test. He never showed me the consent forms that he is required by law to make me sign. I was started on 80 mg per day. (I weigh around 190) He said that I could take the entire day's dose at once. When I picked up my prescription, the pharmacist conveniently forgot to give me the FDA required medication guide. When I picked up the medication, I was under the impression that accutane was an extremely safe drug. "I took it for 2 days. Then I got a bad headache and read about the side effects. I stopped right away. I thought that I was safe having only taken a few pills. However, about 5 days later, I got really depressed and couldn't sleep. My ears started to ring around this time, and a lot of hair around my hairline began to fall out. (The roots of these follicles were black, normally they're white.) My appetite went away around this time as well. A couple of days after this, my libido vanished and I lost virtually all sexual sensation...It has been over a month and a half since my very brief experience with accutane and most of these effects have not improved at all. (I sleep a little better as I am starting to get used to the ear ringing, but that is about it.) "Am I permanently affected from taking an acne medicine for 2 days?" More than 60 posts from Hans follow over the next five years. They show a man becoming increasingly obsessed with the drug Accutane and the effects he believed it was having on his body and his mind. He attributes a series of ailments, including depression, to the medication but the two that he claims most haunt him are a constant ringing in his ears and a loss of sexual sensation. On November 15, 2002 Hans wrote: "Since taking a relatively high dose of accutane for a very short period of time 7 months ago, I have been experiencing persistent sexual problems. I would describe it as a loss of libido and sexual sensation. I have lost virtually all interest in sex. When I do engage in sex or masturbation, the act is no longer pleasurable. I can get an erection and otherwise function normally. The pleasurable sensation is just gone." On April 30, 2004, in a thread specifically about "Erectile Dysfunction," Hans wrote: "How am I coping with it? Not particularly well. You take a drug in order to increase your chances of getting laid, and end up not being able to enjoy getting laid. (Getting an erection isn't that big of a problem - it's the near complete loss of sensation.) I guess you could try to enjoy pleasing the other person, and all that crap. But, still, this side effect is horrible..." As the years pass, Hans tries to become more familiar with both the science and the unsubstantiated claims made about Accutane. He consults with other doctors, who are not able to prove a link between his ailments and the drug he took briefly years before. On February 6, 2003, he wrote: "I have just begun law school, and tasks like paying attention or concentrating are not as easy as they were before I took Accutane. Perhaps I can use whatever legal knowledge I gain to take my revenge... I have nothing else to live for." (The list of side-effects that members of this forum attribute to Accutane is so long that it would be difficult to find a response from drugmaker Roche for every single one. In the past Roche has denied a connection between Accutane and the most serious conditions alleged. "It's our conclusion, along with the outside experts and the FDA, that there is no scientific basis that links Accutane with depression or suicide," a spokesperson told Reuters in 2002.) In a few of these posts, Hans seems to be formulating his rationalization for murder. According to Hans, Dr. Cornbleet is a villain who "deceived" him by knowingly prescribing a dangerous drug without providing any warning of the harmful effects associated with it. Hans also suggests a possible motive for this: Greed. On October 9, 2002 Hans speculated that Dr. Cornbleet was "desperate for patients, and, if I were to go on accutane, I would have to see him every two weeks for a check up." These two claims would seem to be inconsistent, however. Presumably Dr. Cornbleet did not tell Hans that Accutane was an "extremely safe" and "popular drug with no serious side effects" that nevertheless required an intense schedule of bi-monthly monitoring visits. And yet, especially compared to the standards of internet discussion forums, Peterson's writing is frequently clear and concise. At times he even grows impatient with his fellow posters, chastising them for throwing out statistics and claims without citations: "Is there anyone that can tell me where this information is actually published ? I admire the effort of the people that run this site, but you should really provide some adequate form of citation, so we know that these figures aren't just pulled out of the air...I don't doubt the truth of these statements, but in order for this website to be taken seriously, there needs to be some way of verifying the claims that are made on it." After a period of frequent activity in the spring and summer of 2004, Hans disappears from the forum for two years, returning on September 20, 2006, just four weeks before he would travel from New York to Chicago to murder Dr. Cornbleet. On that day he posts two links--one to a depression study reported on the BBC web site and another to a video on YouTube. On October 10, he posts the complete text of an article about Dopamine. The next post is February 7, 2007, more than three months after the murder: "I was deceived by my doctor almost 5 years ago into taking this drug (no consent form, no med guide, no warnings whatsoever). I took a rather high dose for two days. TWO DAYS!!! (albeit an 80 mg undivided dose) Life altering, presumably neurological, problems which I never experienced before have plagued me ever since. "I will never know again what it is like to pleasure a woman because I no longer have any sexual sensation - I will never again experience what silence is due to the constant ringing in my ears - I will never know who I would have become because of what this motherf**king drug has done to my mind. A drug which I should have never been prescribed...In at least some cases, such as mine, this drug just does its damage when its taken, or shortly thereafter, and that's it. No real hope of recovery, doctors are useless, the damage is done. "Doubt my problems and their connection to Accutane all you want - I know I wouldn't believe a word of it if I had never taken the drug and someone told me the story I have told above. The truth is, I'm a rational non-hypochondriac who still can't believe how his life has been changed by this drug." He posted four more times before he turned himself in to St. Martin police in August. On July 2, his second-to-last post he wrote: "Justice will not be found through the legal system. There is no way to objectively verify Accutane-induced permanent neurological problems. Even if there were, it would be near impossible to legally prove causation. Even then, statutes of limitation would have run... If and when the **** ever does hit the fan they will just point out how strenuously they claimed their ignorance about permanent problems. "Would legal justice even be justice, anyway? The people who have profitted from Roche's deception won't be personally brought to justice -- they will be shielded from personal liability... Roche's stock might drop, that's about it, it still would have been rational for those ***holes to deceive regarding Accutane in the first place: its profits over the years have been more than enough. The corrupt FDA, as a gov't institution, can't be held liable.... "There is no foreseeable retributive action in the legal system which would make their fraud regarding Accutane a mistake. Their decisions were economically rational and they know it. Would taking some of their money even be justice? Their lives would go on, just with a little less money. Our lives will never be the same. "If you seek real justice, it will not come through the legal system -- they know this, that's why they continue to deceive and play ignorant. It is the financially rational thing to do..." Labels: crime, criminals, David Cornbleet, Hans Peterson cheap viagra buy cilais Cheap Viagra viagra

Tags: accutane, hans, drug, effect, day